Our findings revealed a previously unknown role for paxillin in the SPC-induced abnormal contraction of VSM, highlighting its potential as a therapeutic target for reducing cardiovascular and cerebrovascular diseases associated with abnormal VSM contraction. This evidence concerns the gene PXN and cerebrovascular disorder.